- Home
- INCY vs BLDR Comparison
INCY vs BLDR Comparison
Compare INCY & BLDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- BLDR
- Stock Information
- Founded
- INCY 1991
- BLDR 1998
- Country
- INCY United States
- BLDR United States
- Employees
- INCY N/A
- BLDR N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- BLDR RETAIL: Building Materials
- Sector
- INCY Health Care
- BLDR Consumer Discretionary
- Exchange
- INCY Nasdaq
- BLDR Nasdaq
- Market Cap
- INCY 17.0B
- BLDR 13.9B
- IPO Year
- INCY 1993
- BLDR 2005
- Fundamental
- Price
- INCY $108.57
- BLDR $105.93
- Analyst Decision
- INCY Buy
- BLDR Buy
- Analyst Count
- INCY 19
- BLDR 17
- Target Price
- INCY $89.19
- BLDR $145.59
- AVG Volume (30 Days)
- INCY 2.9M
- BLDR 2.0M
- Earning Date
- INCY 10-28-2025
- BLDR 10-30-2025
- Dividend Yield
- INCY N/A
- BLDR N/A
- EPS Growth
- INCY 3878.02
- BLDR N/A
- EPS
- INCY 5.90
- BLDR 5.26
- Revenue
- INCY $4,813,105,000.00
- BLDR $15,653,056,000.00
- Revenue This Year
- INCY $19.33
- BLDR N/A
- Revenue Next Year
- INCY $10.47
- BLDR $0.28
- P/E Ratio
- INCY $18.32
- BLDR $20.34
- Revenue Growth
- INCY 18.09
- BLDR N/A
- 52 Week Low
- INCY $53.56
- BLDR $102.60
- 52 Week High
- INCY $108.81
- BLDR $194.36
- Technical
- Relative Strength Index (RSI)
- INCY 83.66
- BLDR 32.12
- Support Level
- INCY $91.16
- BLDR $107.85
- Resistance Level
- INCY $108.81
- BLDR $111.61
- Average True Range (ATR)
- INCY 4.50
- BLDR 4.48
- MACD
- INCY 1.30
- BLDR -0.83
- Stochastic Oscillator
- INCY 98.39
- BLDR 3.08
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About BLDR Builders FirstSource Inc.
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.